Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

194.56 +0.30 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 221,453
Open 196.09
Bid (Size) 189.05 (1)
Ask (Size) 199.99 (1)
Prev. Close 194.26
Today's Range 191.41 - 197.48
52wk Range 126.97 - 248.16
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
From BeiGene, Ltd.
Via Business Wire
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
From BeiGene, Ltd.
Via Business Wire

Performance

YTD
+9.92%
+9.92%
1 Month
-11.53%
-11.53%
3 Month
-1.73%
-1.73%
6 Month
+15.86%
+15.86%
1 Year
+5.21%
+5.21%

More News

Read More
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
From BeiGene, Ltd.
Via Business Wire
Expert Outlook: BeiGene Through The Eyes Of 4 Analysts
Via Benzinga
What Analysts Are Saying About BeiGene Stock
Via Benzinga
BeiGene to Present at the Jefferies London Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
From BeiGene, Ltd.
Via Business Wire
BeiGene Mourns Death of Beloved Board Member Donald Glazer
From BeiGene, Ltd.
Via Business Wire
Top 2 Health Care Stocks That May Plunge In August
Via Benzinga
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
From BeiGene, Ltd.
Via Business Wire
US Listed Chinese Stocks Dominate Another Week - Li Auto, JD.com Among Top 10 Large Cap Gainers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Via Benzinga
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
From BeiGene, Ltd.
Via Business Wire
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
From BeiGene, Ltd.
Via Business Wire
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
Via Benzinga
Exposures Product Safety
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
Via Benzinga
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BeiGene Announces Updates to Commercial Leadership Team
From BeiGene, Ltd.
Via Business Wire
Innovent Bio hopes for plus-sized profits from obesity drug
Via Benzinga
Topics Retirement
Exposures Pension
Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
Via Talk Markets
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
From BeiGene, Ltd.
Via Business Wire
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.